Guardian Partners’s AbCellera Biologics ABCL Stock Holding History

Guardian Partners’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.7M	Hold	595,998	–	–	0.77%	40
2026 Q2	$4.68M	Sell	595,998 -1,190,417	-67%	-$5.82M	0.42%	54
2026 Q1	$6.25M	Buy	1,786,415 +1	+0%	+$4	0.52%	51
2025 Q4	$5.82M	Hold	1,786,414	–	–	0.47%	55
2025 Q3	$10.6M	Hold	1,786,414	–	–	0.9%	38
2025 Q2	$7.54M	Hold	1,786,414	–	–	0.68%	51
2025 Q1	$4.52M	Hold	1,786,414	–	–	0.47%	65
2024 Q4	$5.41M	Buy	+1,786,414	New	+$4.97M	0.55%	57

Other funds holding ABCL

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 32.98% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $53.6B AUM 32.29% 1-Year Est. Return

Citizens Financial Group Providence, Rhode Island $8.58B AUM 20.32% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

XML Financial Bethesda, Maryland $1.39B AUM 19.06% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

VestGen Advisors Inverness, Illinois $3.25B AUM 30.95% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Guardian Partners's ABCL Position: Q3 2026 in Review

Guardian Partners held its AbCellera Biologics (ABCL) position steady in Q3 2026 at 595,998 shares worth $8.7M. The position accounts for 0.77% of the portfolio, ranked #40.

Guardian Partners first reported a position in ABCL in Q4 2024 and has held it in 8 quarters since. The position peaked at $10.6M in Q3 2025. 30 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

Guardian Partners held 595,998 shares of AbCellera Biologics worth $8.7M as of Q3 2026.
Guardian Partners left its AbCellera Biologics share count unchanged in Q3 2026.
AbCellera Biologics made up 0.77% of Guardian Partners's portfolio in Q3 2026, its #40 holding.
Guardian Partners first reported a position in AbCellera Biologics in Q4 2024 and has held it in 8 quarters since.
Guardian Partners's AbCellera Biologics position peaked at $10.6M in Q3 2025.
30 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Guardian Partners's 13F filing for Q3 2026, filed 21 Oct 2026.